Cytokinetics reports Q2 revenue of $28.6M, exceeding expectations by $11.14M amid a 57.2% year-over-year decline.
Cytokinetics posted a Q2 GAAP EPS loss of $1.50, beating estimates by $0.14. Revenue reached $28.6M, surpassing expectations by $11.14M despite a 57.2% year-over-year decline.
The company had not previously disclosed Q2 consensus figures, but the results reflect a significant outperformance relative to market expectations. Revenue in the comparable period last year was not provided for direct comparison.
Shares rose 3.20% following the announcement. Cytokinetics also updated its full-year 2026 financial guidance.